Today: 8 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 26 September 2025 - 17 October 2025

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Stock Hits a 52-Week Low on Legal Woes Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly (up about 0.6% in pre-market trading) after the rout stocktwits.com. Still, at roughly 40% below its IPO price, the Johnson & Johnson spinoff has seen its market capitalization shrink to about $30–31 billion reuters.com. This dramatic sell-off came despite broader markets being relatively calm – the S&P
17 October 2025
··
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonistreuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeuticsreuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra (JNJ-2113) since a 2017 collaboration dealreuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early confidence in the
10 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 (another +6.8%) investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive
2 October 2025
··
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Stock Price and Recent Performance Pfizer’s stock has struggled in 2025, hovering near multi-year lows. At ~$23.60 per share in late September, PFE has declined about 9% since January, underperforming the S&P 500 (which is up modestly) and lagging the broader healthcare sector. Over the past 12 months, the stock is down roughly 18%. The 52-week high was $30.43, and shares now sit not far above their year’s low of $20.92 stockanalysis.com. By market capitalization (~$134 billion), Pfizer remains one of the world’s largest pharmaceutical companies, but its valuation has compressed significantly from pandemic-era peaks. This underperformance stems largely from
26 September 2025
··
1 … 6 7 8

Stock Market Today

Seatrium share price slips: what traders watch before SGX reopens Monday

Seatrium share price slips: what traders watch before SGX reopens Monday

8 February 2026
Seatrium shares closed down 1% at S$2.06 Friday ahead of full-year results due Feb. 26. The company marked a key offshore wind platform milestone with TenneT and GE Vernova this week. Investors are watching for updates on project progress, cash flow, and new orders as markets reopen Monday.
CapitaLand Investment share price jumps into earnings week as 9CI closes at S$3.12

CapitaLand Investment share price jumps into earnings week as 9CI closes at S$3.12

8 February 2026
CapitaLand Investment shares closed up 1.3% at S$3.12 on Friday, outperforming the STI, which fell 0.83%. CapitaLand Integrated Commercial Trust reported a 16.4% rise in second-half distributable income to S$449 million and a 9.4% increase in distribution per unit. Full-year results for CapitaLand Investment are due Feb. 11. Markets are closed for the weekend.
Hongkong Land (SGX:H78) slides 4% despite fresh buyback as March results loom

Hongkong Land (SGX:H78) slides 4% despite fresh buyback as March results loom

8 February 2026
Hongkong Land shares fell 4.2% to $8.18 Friday, reversing earlier gains after hitting a decade high of $9.12 on Feb. 4. The company disclosed repurchases of 170,000 shares for cancellation at average prices above Friday’s close. Investors await March 5 annual results and details on an expanded $650 million buyback program. Trading volume stayed high.
Go toTop